MicroRNA ‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MicroRNA ‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer

Published:2020-09-07 Issue:10 Volume:11 Page:2975-2982
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Katakura Seigo¹,Kobayashi Nobuaki¹^ORCID,Hashimoto Hisashi¹,Kamimaki Chisato¹,Tanaka Katsushi¹,Kubo Sousuke¹,Nakashima Kentaro¹,Teranishi Shuhei²,Manabe Saki²,Watanabe Keisuke¹^ORCID,Horita Nobuyuki¹^ORCID,Hara Yu¹^ORCID,Yamamoto Masaki²^ORCID,Kudo Makoto²,Piao Hongmei³,Kaneko Takeshi¹

Affiliation:

1. Department of Pulmonology Yokohama City University Graduate School of Medicine Yokohama Japan

2. Respiratory Disease Center Yokohama City University Medical Center Yokohama Japan

3. Department of Respiratory Medicine Affiliated Hospital of Yanbian University Yanji China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13653

Reference34 articles.

1. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

3. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

4. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

5. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer;Biomedicine & Pharmacotherapy;2024-04

2. A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study;Frontiers in Medicine;2022-10-31

3. Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review);International Journal of Oncology;2022-09-20

4. Extracellular vesicles and particles impact the systemic landscape of cancer;The EMBO Journal;2022-09-02

5. Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events;Non-coding RNA Research;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3